Use the hyperlinks, where available to access additional clinical trial information.
An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused PG545 in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer
Scientia Clinical Research Limited
This trial includes a dose escalation and dose expansion stage. In Stage 1 (dose escalation) patients with advanced or metastatic solid tumours will receive PG545 25, 50 or 100 mg once weekly via IV infusion and Nivolumab 240 mg every two weeks via IV infusion. In Stage 2 (dose expansion) patients with metastatic pancreas cancer will receive the recommended PG545 dose, identified through Stage 1, once weekly via IV infusion and Nivolumab 240 mg every two weeks via IV infusion.